# Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

> **NCT00002580** · PHASE3 · COMPLETED · sponsor: **Scottish Cancer Therapy Network** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** fluorouracil
- **DRUG:** goserelin acetate
- **DRUG:** leuprolide acetate
- **DRUG:** methotrexate
- **DRUG:** tamoxifen citrate
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** laparoscopic surgery
- **PROCEDURE:** oophorectomy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002580
- **Lead sponsor:** Scottish Cancer Therapy Network
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002580, "Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00002580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*